Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Specials
Spring Home & Garden Show
Home & Realty
Outdoor Guide
Women
Spring on the Road
Spring Wellness
Premier Home Stylle Tour 2024
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
2024 Readersâ Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by AVROBIO, Inc.
< Previous
1
2
Next >
AVROBIO Announces Preclinical Gene Therapy Data for Pompe Disease at American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
May 18, 2022
From
AVROBIO, Inc.
Via
Business Wire
Tickers
AVRO
AVROBIO Reports Positive Data From Phase 1/2 Clinical Trial of Investigational Gene Therapy for Cystinosis, Including New Interim Data on Neurocognitive Measures
May 17, 2022
From
AVROBIO, Inc.
Via
Business Wire
Tickers
AVRO
AVROBIO to Present at the H.C. Wainwright Global Investment Conference
May 16, 2022
From
AVROBIO, Inc.
Via
Business Wire
Tickers
AVRO
AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 06, 2022
From
AVROBIO, Inc.
Via
Business Wire
Tickers
AVRO
AVROBIO to Present New Clinical and Preclinical Data at the ASGCT 25th Annual Meeting
May 03, 2022
From
AVROBIO, Inc.
Via
Business Wire
Tickers
AVRO
AVROBIO Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
April 06, 2022
From
AVROBIO, Inc.
Via
Business Wire
Tickers
AVRO
AVROBIO to Present at the 21st Annual Needham Virtual Healthcare Conference
April 05, 2022
From
AVROBIO, Inc.
Via
Business Wire
Tickers
AVRO
AVROBIO Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Provides Business Update
March 17, 2022
From
AVROBIO, Inc.
Via
Business Wire
Tickers
AVRO
AVROBIO Reports Interim Data from Phase 1/2 Clinical Trial of Investigational Gene Therapy for Cystinosis
February 09, 2022
From
AVROBIO, Inc.
Via
Business Wire
Tickers
AVRO
AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 04, 2022
From
AVROBIO, Inc.
Via
Business Wire
Tickers
AVRO
AVROBIO Announces the Appointment of Sean O’Bryan as Chief Regulatory Officer
February 01, 2022
From
AVROBIO, Inc.
Via
Business Wire
Tickers
AVRO
AVROBIO to Present at Cowen’s 2nd Annual Genetic Medicines Summit
January 28, 2022
From
AVROBIO, Inc.
Via
Business Wire
Tickers
AVRO
AVROBIO to Present New Data from Phase 1/2 Clinical Trial in Cystinosis at WORLDSymposium™ 2022
January 27, 2022
From
AVROBIO, Inc.
Via
Business Wire
Tickers
AVRO
AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 06, 2022
From
AVROBIO, Inc.
Via
Business Wire
Tickers
AVRO
AVROBIO Reprioritizes Pipeline Programs
January 04, 2022
From
AVROBIO, Inc.
Via
Business Wire
Tickers
AVRO
AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 07, 2021
From
AVROBIO, Inc.
Via
Business Wire
Tickers
AVRO
AVROBIO Presents Clinician Experience with FAB-GT Clinical Trial and Updated Safety Data for Investigational Gene Therapies in Fabry Disease and Gaucher Disease Type 1
November 24, 2021
From
AVROBIO, Inc.
Via
Business Wire
Tickers
AVRO
AVROBIO to Present at Two Upcoming Investor Conferences in November
November 09, 2021
From
AVROBIO, Inc.
Via
Business Wire
Tickers
AVRO
AVROBIO to Present Clinical and Preclinical Data at the 14th ICIEM Conference
November 08, 2021
From
AVROBIO, Inc.
Via
Business Wire
Tickers
AVRO
AVROBIO Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
November 05, 2021
From
AVROBIO, Inc.
Via
Business Wire
Tickers
AVRO
AVROBIO Reports Third Quarter 2021 Financial Results and Provides Business Update
November 04, 2021
From
AVROBIO, Inc.
Via
Business Wire
Tickers
AVRO
AVROBIO Receives Rare Pediatric Disease Designation from the U.S. FDA for AVR-RD-05, a Gene Therapy for Mucopolysaccharidosis Type II (MPSII) or Hunter Syndrome
November 03, 2021
From
AVROBIO, Inc.
Via
Business Wire
Tickers
AVRO
AVROBIO Announces the Appointment of Essra Ridha, M.D., MRCP, FFPM, as Chief Medical Officer
October 26, 2021
From
AVROBIO, Inc.
Via
Business Wire
Tickers
AVRO
AVROBIO to Present at the Jefferies Virtual Gene Therapy/Editing Summit
October 20, 2021
From
AVROBIO, Inc.
Via
Business Wire
Tickers
AVRO
AVROBIO Reports New Interim Safety Data Across Investigational Gene Therapies for Fabry and Gaucher Disease Type 1
October 19, 2021
From
AVROBIO, Inc.
Via
Business Wire
Tickers
AVRO
AVROBIO to Present New Clinical and Preclinical Data Across Multiple Programs at the ESGCT 28th Annual Congress
October 06, 2021
From
AVROBIO, Inc.
Via
Business Wire
Tickers
AVRO
AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 05, 2021
From
AVROBIO, Inc.
Via
Business Wire
Tickers
AVRO
AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 03, 2021
From
AVROBIO, Inc.
Via
Business Wire
Tickers
AVRO
AVROBIO to Participate at Four Upcoming Investor Conferences
September 01, 2021
From
AVROBIO, Inc.
Via
Business Wire
Tickers
AVRO
AVROBIO Reports Second Quarter 2021 Financial Results and Provides Business Update
August 05, 2021
From
AVROBIO, Inc.
Via
Business Wire
Tickers
AVRO
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.